Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome

特瑞氟米特 医学 磁共振成像 多发性硬化 白质 临床孤立综合征 中枢神经系统 放射科 内科学 精神科 病理 芬戈莫德
作者
Christine Lebrun‐Frénay,Aksel Sıva,Maria Pia Sormani,Cassandre Landes-Château,Lydiane Mondot,Francesca Bovis,Patrick Vermersch,Caroline Papeix,Éric Thouvenot,Pierre Labauge,Françoise Durand‐Dubief,Hüsnü Efendi,Emmanuelle Le Page,Murat Terzi,Nathalie Derache,Bertrand Bourre,Robert Hoepner,Rana Karabudak,de Sèze,Jonathan Ciron
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:80 (10): 1080-1080 被引量:86
标识
DOI:10.1001/jamaneurol.2023.2815
摘要

Importance: Radiologically isolated syndrome (RIS) represents the earliest detectable preclinical phase of multiple sclerosis (MS) punctuated by incidental magnetic resonance imaging (MRI) white matter anomalies within the central nervous system. Objective: To determine the time to onset of symptoms consistent with MS. Design, Setting, and Participants: From September 2017 to October 2022, this multicenter, double-blind, phase 3, randomized clinical trial investigated the efficacy of teriflunomide in delaying MS in individuals with RIS, with a 3-year follow-up. The setting included referral centers in France, Switzerland, and Turkey. Participants older than 18 years meeting 2009 RIS criteria were randomly assigned (1:1) to oral teriflunomide, 14 mg daily, or placebo up to week 96 or, optionally, to week 144. Interventions: Clinical, MRI, and patient-reported outcomes (PROs) were collected at baseline and yearly until week 96, with an optional third year in the allocated arm if no symptoms have occurred. Main outcomes: Primary analysis was performed in the intention-to-treat population, and safety was assessed accordingly. Secondary end points included MRI outcomes and PROs. Results: Among 124 individuals assessed for eligibility, 35 were excluded for declining to participate, not meeting inclusion criteria, or loss of follow-up. Eighty-nine participants (mean [SD] age, 37.8 [12.1] years; 63 female [70.8%]) were enrolled (placebo, 45 [50.6%]; teriflunomide, 44 [49.4%]). Eighteen participants (placebo, 9 [50.0%]; teriflunomide, 9 [50.0%]) discontinued the study, resulting in a dropout rate of 20% for adverse events (3 [16.7%]), consent withdrawal (4 [22.2%]), loss to follow-up (5 [27.8%]), voluntary withdrawal (4 [22.2%]), pregnancy (1 [5.6%]), and study termination (1 [5.6%]). The time to the first clinical event was significantly extended in the teriflunomide arm compared with placebo, in both the unadjusted (hazard ratio [HR], 0.37; 95% CI, 0.16-0.84; P = .02) and adjusted (HR, 0.28; 95% CI, 0.11-0.71; P = .007) analysis. Secondary imaging end point outcomes including the comparison of the cumulative number of new or newly enlarging T2 lesions (rate ratio [RR], 0.57; 95% CI, 0.27-1.20; P = .14), new gadolinium-enhancing lesions (RR, 0.33; 95% CI, 0.09-1.17; P = .09), and the proportion of participants with new lesions (odds ratio, 0.72; 95% CI, 0.25-2.06; P = .54) were not significant. Conclusion and Relevance: Treatment with teriflunomide resulted in an unadjusted risk reduction of 63% and an adjusted risk reduction of 72%, relative to placebo, in preventing a first clinical demyelinating event. These data suggest a benefit to early treatment in the MS disease spectrum. Trial Registration: ClinicalTrials.gov Identifier: NCT03122652.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lq完成签到 ,获得积分10
刚刚
wangjue完成签到,获得积分10
3秒前
李健的小迷弟的应助被Vincent采纳,获得10
4秒前
5秒前
10秒前
wu完成签到 ,获得积分10
15秒前
JamesPei的应助被Vincent采纳,获得10
15秒前
苹果元灵完成签到,获得积分10
16秒前
16秒前
666666神花露水完成签到 ,获得积分10
19秒前
NexusExplorer的应助被Vincent采纳,获得10
22秒前
22秒前
yu完成签到 ,获得积分10
23秒前
29秒前
爆米花的应助被Vincent采纳,获得10
31秒前
35秒前
HAPPY完成签到,获得积分10
36秒前
桐桐的应助被Vincent采纳,获得10
37秒前
keleboys完成签到 ,获得积分10
39秒前
HMZ完成签到 ,获得积分10
41秒前
42秒前
HU完成签到 ,获得积分10
44秒前
45秒前
49秒前
小尾巴完成签到 ,获得积分10
52秒前
章鱼行者完成签到,获得积分10
52秒前
鲁文杰发布了新的文献求助10
53秒前
Maestro_S的应助被Vincent采纳,获得10
55秒前
56秒前
万能图书馆的应助被Vincent采纳,获得10
1分钟前
1分钟前
水静完成签到,获得积分10
1分钟前
川川完成签到 ,获得积分10
1分钟前
1分钟前
科研通AI6.4的应助被Vincent采纳,获得10
1分钟前
1分钟前
标致访旋完成签到,获得积分10
1分钟前
烂漫墨镜完成签到 ,获得积分10
1分钟前
20230054发布了新的文献求助10
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190366
求助须知:如何正确求助?哪些是违规求助? 9577437
关于积分的说明 21852521
捐赠科研通 7788988
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560144
邀请新用户注册赠送积分活动 2482995